OSTEOSARCOMA, Pediatric Clinics of North America, vol.44, issue.4, pp.973-89, 1997. ,
DOI : 10.1016/S0031-3955(05)70540-X
Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy, Cancer, issue.6, pp.49-1221, 1982. ,
Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy, Cancer, vol.84, issue.12, pp.2701-2707, 2006. ,
DOI : 10.1002/cncr.21937
On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy, European Journal of Cancer, vol.33, issue.11, pp.33-1725, 1997. ,
DOI : 10.1016/S0959-8049(97)00252-9
Prognostic Relevance of Increased Angiogenesis in Osteosarcoma, Clinical Cancer Research, vol.10, issue.24, pp.8531-8538, 2004. ,
DOI : 10.1158/1078-0432.CCR-04-0969
Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma, Cell, vol.79, issue.2, pp.315-343, 1994. ,
DOI : 10.1016/0092-8674(94)90200-3
Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth, Cell, vol.88, issue.2, pp.277-85, 1997. ,
DOI : 10.1016/S0092-8674(00)81848-6
Cloning, Expression, andin VitroActivity of Human Endostatin, Biochemical and Biophysical Research Communications, vol.258, issue.2, pp.345-52, 1999. ,
DOI : 10.1006/bbrc.1999.0595
Mouse endostatin inhibits the formation of lung and liver metastases, Cancer Res, vol.59, issue.24, pp.6251-6257, 1999. ,
Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth, Cancer Res, vol.60, issue.8, pp.2190-2196, 2000. ,
Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model, Cancer Res, issue.20, pp.61-7669, 2001. ,
Adeno-associated virus???mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo, Cancer Gene Therapy, vol.9, issue.6, pp.513-534, 2002. ,
DOI : 10.1038/sj.cgt.7700463
Effect of Retroviral Endostatin Gene Transfer on Subcutaneous and Intraperitoneal Growth of Murine Tumors, JNCI Journal of the National Cancer Institute, vol.93, issue.13, pp.93-1014, 2001. ,
DOI : 10.1093/jnci/93.13.1014
Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin, Clin Cancer Res, issue.711, pp.3366-74, 2001. ,
Phase I Clinical Trial of Recombinant Human Endostatin Administered as a Short Intravenous Infusion Repeated Daily, Journal of Clinical Oncology, vol.20, issue.18, pp.20-3772, 2002. ,
DOI : 10.1200/JCO.2002.02.082
Phase I Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors, Journal of Clinical Oncology, vol.20, issue.18, pp.3792-803, 2002. ,
DOI : 10.1200/JCO.2002.11.061
Phase I Pharmacokinetic and Pharmacodynamic Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors, Journal of Clinical Oncology, vol.21, issue.2, pp.223-254, 2003. ,
DOI : 10.1200/JCO.2003.12.120
Matrix Metalloproteinases Participate in Osteosarcoma Invasion, Journal of Surgical Research, vol.127, issue.2, pp.151-157, 2005. ,
DOI : 10.1016/j.jss.2004.12.016
Molecular Pathogenesis of Osteosarcoma, DNA and Cell Biology, vol.26, issue.1, pp.1-18, 2007. ,
DOI : 10.1089/dna.2006.0505
PI3-K/Akt-mediated anoikis resistance of human osteosarcoma cells requires Src activation, European Journal of Cancer, vol.42, issue.10, pp.42-1491, 2006. ,
DOI : 10.1016/j.ejca.2006.03.007
Inhibition of Src Phosphorylation Alters Metastatic Potential of Osteosarcoma In vitro but not In vivo, Clinical Cancer Research, vol.15, issue.10, pp.15-3416, 2009. ,
DOI : 10.1158/1078-0432.CCR-08-1657
Src kinases as therapeutic targets for cancer, Nature Reviews Clinical Oncology, vol.439, issue.10, pp.587-95, 2009. ,
DOI : 10.1038/nrclinonc.2009.129
Wnt Inhibitory Factor 1 Decreases Tumorigenesis and Metastasis in Osteosarcoma, Molecular Cancer Therapeutics, vol.9, issue.3, pp.731-772, 2010. ,
DOI : 10.1158/1535-7163.MCT-09-0147
Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells, Journal of Orthopaedic Research, vol.65, issue.7, pp.25-964, 2007. ,
DOI : 10.1002/jor.20356
Notch signaling contributes to the pathogenesis of human osteosarcomas, Human Molecular Genetics, vol.18, issue.8, pp.1464-70, 2009. ,
DOI : 10.1093/hmg/ddp057
How the NOTCH Pathway Contributes to the Ability of Osteosarcoma Cells to Metastasize, Cancer Treat Res, vol.152, pp.479-96, 2009. ,
DOI : 10.1007/978-1-4419-0284-9_28
Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation, British Journal of Cancer, vol.51, issue.12, pp.1957-65, 2009. ,
DOI : 10.1038/35017108
Critical Role of Notch Signaling in Osteosarcoma Invasion and Metastasis, Clinical Cancer Research, vol.14, issue.10, pp.2962-2971, 2008. ,
DOI : 10.1158/1078-0432.CCR-07-1992
Expression of MMP2, MMP9, MT1-MMP, TIMP1, and TIMP2 mRNA in valvular lesions of the heart, The Journal of Pathology, vol.266, issue.2, pp.225-256, 2001. ,
DOI : 10.1002/path.850
Relationship between expression of matrix metalloproteinase-2 and matrix metalloproteinase-9 and invasion ability of cervical cancer cells, Oncology Reports, issue.93, pp.565-574, 2002. ,
DOI : 10.3892/or.9.3.565
Functional Significance of MMP-9 in Tumor Necrosis Factor-Induced Proliferation and Branching Morphogenesis of Mammary Epithelial Cells, Endocrinology, vol.141, issue.10, pp.141-3764, 2000. ,
DOI : 10.1210/en.141.10.3764
Trypsin in colorectal cancer: molecular biological mechanisms of proliferation, invasion, and metastasis, The Journal of Pathology, vol.16, issue.2, pp.147-56, 2006. ,
DOI : 10.1002/path.1999
Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. Pediatr Blood Cancer, pp.410-415, 2004. ,
Inhibition of matrix metalloproteinase-14 in osteosarcoma cells by clodronate, Journal of Surgical Research, vol.111, issue.1, pp.45-52, 2003. ,
DOI : 10.1016/S0022-4804(03)00086-6
Risedronate inhibits human osteosarcoma cell invasion Bisphosphonates: new therapeutic agents for the treatment of bone tumors, J Exp Clin Cancer Res Trends Mol Med, issue.7, pp.10-337, 2004. ,
Therapeutic Approach of Primary Bone Tumours by Bisphosphonates, Current Pharmaceutical Design, vol.16, issue.27, pp.2981-2988, 2010. ,
DOI : 10.2174/138161210793563554
URL : https://hal.archives-ouvertes.fr/inserm-00511241
Disulfiram Suppresses Invasive Ability of Osteosarcoma Cells Via the Inhibition of MMP-2 and MMP-9 Expression, BMB Reports, vol.40, issue.6, pp.40-1069, 2007. ,
DOI : 10.5483/BMBRep.2007.40.6.1069
Roles of Wnt signalling in bone growth, remodelling, skeletal disorders and fracture repair, Journal of Cellular Physiology, vol.40, issue.3, pp.578-87, 2008. ,
DOI : 10.1002/jcp.21342
Canonical Wnt Signaling in Differentiated Osteoblasts Controls Osteoclast Differentiation, Developmental Cell, vol.8, issue.5, pp.751-64, 2005. ,
DOI : 10.1016/j.devcel.2005.02.017
Secreted antagonists of the Wnt signalling pathway Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton, J Cell Sci Endocrinology, issue.1166, pp.148-2635, 2003. ,
Mechanisms of Anabolic Therapies for Osteoporosis, New England Journal of Medicine, vol.357, issue.9, pp.905-921, 2007. ,
DOI : 10.1056/NEJMra067395
A new secreted protein that binds to Wnt proteins and inhibits their activities, Nature, issue.6726, pp.398-431, 1999. ,
Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells, Nature, vol.398, issue.6726, pp.422-428, 1999. ,
Identification of c-MYC as a Target of the APC Pathway, Science, vol.281, issue.5382, pp.281-1509, 1998. ,
DOI : 10.1126/science.281.5382.1509
The metalloproteinase matrilysin is a target of ??-catenin transactivation in intestinal tumors, Oncogene, vol.18, issue.18, pp.2883-91, 1999. ,
DOI : 10.1038/sj.onc.1202627
Survivin and molecular pathogenesis of colorectal cancer, The Lancet, vol.362, issue.9379, pp.205-214, 2003. ,
DOI : 10.1016/S0140-6736(03)13910-4
Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis, Int J Cancer Clin Exp Metastasis, vol.102, issue.46, pp.338-380, 2002. ,
Frequent ??-Catenin Abnormalities in Bone and Soft-tissue Tumors, Japanese Journal of Cancer Research, vol.58, issue.2, pp.205-214, 1999. ,
DOI : 10.1111/j.1349-7006.1999.tb00734.x
Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma, International Journal of Cancer, vol.21, issue.1, pp.106-117, 2004. ,
DOI : 10.1002/ijc.11677
Dickkopf 3 Inhibits Invasion and Motility of Saos-2 Osteosarcoma Cells by Modulating the Wnt-??-Catenin Pathway, Cancer Research, vol.64, issue.8, pp.2734-2743, 2000. ,
DOI : 10.1158/0008-5472.CAN-03-1952
Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/beta-catenin antagonists against human osteosarcoma cells, Invest New Drugs, issue.6, pp.28-766, 2010. ,
Wnt Inhibitory Factor-1 Is Silenced by Promoter Hypermethylation in Human Lung Cancer, Cancer Research, vol.64, issue.14, pp.4717-4737, 2004. ,
DOI : 10.1158/0008-5472.CAN-04-1389
Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell lines, Biochemical and Biophysical Research Communications, vol.341, issue.2, pp.635-675, 2006. ,
DOI : 10.1016/j.bbrc.2005.12.220
Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer, Carcinogenesis, vol.27, issue.7, pp.1341-1349, 2006. ,
DOI : 10.1093/carcin/bgi379
Notch Signaling: Cell Fate Control and Signal Integration in Development, Science, vol.284, issue.5415, pp.284-770, 1999. ,
DOI : 10.1126/science.284.5415.770
The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism, Cell, vol.137, issue.2, pp.216-249, 2009. ,
DOI : 10.1016/j.cell.2009.03.045
HES and HERP families: Multiple effectors of the notch signaling pathway, Journal of Cellular Physiology, vol.271, issue.3, pp.237-55, 2003. ,
DOI : 10.1002/jcp.10208
Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers., Proceedings of the National Academy of Sciences, vol.92, issue.15, pp.92-6981, 1995. ,
DOI : 10.1073/pnas.92.15.6981
Identification of two juxtamembrane autophosphorylation sites in the PDGF betareceptor ; involvement in the interaction with Src family tyrosine kinases, EMBO J, vol.12, issue.6, pp.2257-64, 1993. ,
The interplay between Src and integrins in normal and tumor biology, Oncogene, vol.23, issue.48, pp.7928-7974, 2004. ,
DOI : 10.1038/sj.onc.1208080
Dasatinib in Imatinib-Resistant Philadelphia Chromosome???Positive Leukemias, New England Journal of Medicine, vol.354, issue.24, pp.2531-2572, 2006. ,
DOI : 10.1056/NEJMoa055229
Dasatinib (BMS-354825) Tyrosine Kinase Inhibitor Suppresses Invasion and Induces Cell Cycle Arrest and Apoptosis of Head and Neck Squamous Cell Carcinoma and Non-Small Cell Lung Cancer Cells, Clinical Cancer Research, vol.11, issue.19, pp.6924-6956, 2005. ,
DOI : 10.1158/1078-0432.CCR-05-0757
Dasatinib (BMS-354825), a Dual SRC/ABL Kinase Inhibitor, Inhibits the Kinase Activity of Wild-Type, Juxtamembrane, and Activation Loop Mutant KIT Isoforms Associated with Human Malignancies, Cancer Research, vol.66, issue.1, pp.473-81, 2006. ,
DOI : 10.1158/0008-5472.CAN-05-2050
Dasatinib Inhibits Migration and Invasion in Diverse Human Sarcoma Cell Lines and Induces Apoptosis in Bone Sarcoma Cells Dependent on Src Kinase for Survival, Cancer Research, vol.67, issue.6, pp.67-2800, 2007. ,
DOI : 10.1158/0008-5472.CAN-06-3469
Fas and Fas Ligand Interactions Suppress Melanoma Lung Metastasis, The Journal of Experimental Medicine, vol.15, issue.9, pp.1717-1740, 1998. ,
DOI : 10.1084/jem.184.2.429
Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells, J Immunol, issue.8, pp.161-3957, 1998. ,
IFN-??-Dependent Delay of In Vivo Tumor Progression by Fas Overexpression on Murine Renal Cancer Cells, The Journal of Immunology, vol.164, issue.1, pp.231-240, 2000. ,
DOI : 10.4049/jimmunol.164.1.231
Fas Expression in Lung Metastasis From Osteosarcoma Patients, Journal of Pediatric Hematology/Oncology, vol.27, issue.11, pp.611-616, 2005. ,
DOI : 10.1097/01.mph.0000188112.42576.df
Fas expression inversely correlates with metastatic potential in osteosarcoma cells, Oncology Reports, vol.9, issue.4, pp.823-830, 2002. ,
DOI : 10.3892/or.9.4.823
The CD95 Receptor: Apoptosis Revisited, Cell, vol.129, issue.3, pp.447-50, 2007. ,
DOI : 10.1016/j.cell.2007.04.031
URL : https://hal.archives-ouvertes.fr/hal-00318978
CD95 promotes tumour growth, Nature, issue.7297, pp.465-492, 2010. ,
DOI : 10.1038/nature09897
The Many Roles of FAS Receptor Signaling in the Immune System, Immunity, vol.30, issue.2, pp.180-92, 2009. ,
DOI : 10.1016/j.immuni.2009.01.001
DEATH AND ANTI-DEATH: TUMOUR RESISTANCE TO APOPTOSIS, Nature Reviews Cancer, vol.2, issue.4, pp.277-88, 2002. ,
DOI : 10.1038/nrc776
Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary, Clin Cancer Res, issue.915, pp.5442-53, 2003. ,
Fas-Negative Osteosarcoma Tumor Cells Are Selected during Metastasis to the Lungs: The Role of the Fas Pathway in the Metastatic Process of Osteosarcoma, Molecular Cancer Research, vol.5, issue.10, pp.991-1000, 2007. ,
DOI : 10.1158/1541-7786.MCR-07-0007
Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells, Cancer Res, issue.10, pp.61-4066, 2001. ,
Increased Fas Expression Reduces the Metastatic Potential of Human Osteosarcoma Cells, Clinical Cancer Research, vol.10, issue.23, pp.8114-8123, 2004. ,
DOI : 10.1158/1078-0432.CCR-04-0353
Interleukin-12 Up-Regulates Fas Expression in Human Osteosarcoma and Ewing's Sarcoma Cells by Enhancing Its Promoter Activity, Molecular Cancer Research, vol.3, issue.12, pp.685-91, 2005. ,
DOI : 10.1158/1541-7786.MCR-05-0092
Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases, Cancer, vol.58, issue.6, pp.1382-1390, 2006. ,
DOI : 10.1002/cncr.21744
Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases, Expert Review of Anticancer Therapy, vol.8, issue.2, pp.151-160, 2008. ,
DOI : 10.1586/14737140.8.2.151
Interleukin-18: biological properties and clinical implications, Eur Cytokine Netw, vol.11, issue.1, pp.15-26, 2000. ,
Interleukin 18--interferon gamma inducing factor--a novel player in tumour immunotherapy? Cytokine, pp.332-340, 2000. ,
Interleukin-18 acts as an angiogenesis and tumor suppressor, FASEB J, vol.13, issue.15, pp.2195-202, 1999. ,
Interleukin 18 enhances Fas ligand expression and induces apoptosis in Fasexpressing human myelomonocytic KG-1 cells, Anticancer Res, issue.5A, pp.17-3253, 1997. ,
Effect of interleukin-18 on metastasis of mouse osteosarcoma cells, Cancer Immunology, Immunotherapy, vol.9, issue.9, pp.1151-1159, 2006. ,
DOI : 10.1007/s00262-005-0097-3
Immunotherapy with Interleukin-18 in Combination with Preoperative Chemotherapy with Ifosfamide Effectively Inhibits Postoperative Progression of Pulmonary Metastases in a Mouse Osteosarcoma Model, Tumor Biology, vol.30, issue.4, pp.176-84, 2009. ,
DOI : 10.1159/000236410
Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix, Science, vol.267, issue.5199, pp.891-894, 1995. ,
DOI : 10.1126/science.7531366
Apoptotic signaling during initiation of detachment-induced apoptosis ("anoikis") of primary human intestinal epithelial cells, Cell Growth Differ, vol.12, issue.3, pp.147-55, 2001. ,
Anoikis mechanisms, Current Opinion in Cell Biology, vol.13, issue.5, pp.555-62, 2001. ,
DOI : 10.1016/S0955-0674(00)00251-9
Acquisition of anoikis resistance in human osteosarcoma cells, European Journal of Cancer, vol.39, issue.16, pp.39-2395, 2003. ,
DOI : 10.1016/S0959-8049(03)00575-6
Anoikis: Cancer and the homeless cell, Nature, vol.58, issue.7003, pp.430-973, 2004. ,
DOI : 10.1074/jbc.M404115200
Metastasis: a question of life or death, Nature Reviews Cancer, vol.5, issue.6, pp.449-58, 2006. ,
DOI : 10.1038/nrc1886
A Signaling Adapter Function for ??6??4 Integrin in the Control of HGF-Dependent Invasive Growth, Cell, vol.107, issue.5, pp.643-54, 2001. ,
DOI : 10.1016/S0092-8674(01)00567-0
Integrin ??4 signaling promotes tumor angiogenesis, Cancer Cell, vol.6, issue.5, pp.471-83, 2004. ,
DOI : 10.1016/j.ccr.2004.09.029
??4 Integrin Amplifies ErbB2 Signaling to Promote Mammary Tumorigenesis, Cell, vol.126, issue.3, pp.489-502, 2006. ,
DOI : 10.1016/j.cell.2006.05.047
Beta4 integrin promotes osteosarcoma metastasis and interacts with ezrin, Oncogene, vol.4, issue.38, pp.3401-3412, 2009. ,
DOI : 10.1158/0008-5472.CAN-04-3135
Anoikis: A necessary death program for anchorage-dependent cells, Biochemical Pharmacology, vol.76, issue.11, pp.76-1352, 2008. ,
DOI : 10.1016/j.bcp.2008.07.023
Switch from ??v??5 to ??v??6 integrin expression protects squamous cell carcinomas from anoikis, The Journal of Cell Biology, vol.105, issue.3, pp.419-450, 2004. ,
DOI : 10.1093/emboj/cdf399
Structure of caveolae, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol.1746, issue.3, pp.1746-334, 2005. ,
DOI : 10.1016/j.bbamcr.2005.08.008
Caveolin, a protein component of caveolae membrane coats, Cell, vol.68, issue.4, pp.673-82, 1992. ,
DOI : 10.1016/0092-8674(92)90143-Z
Caveolin-Enriched Membrane Signaling Complexes in Human and Murine Osteoblasts, Journal of Bone and Mineral Research, vol.135, issue.4, pp.15-2380, 2000. ,
DOI : 10.1359/jbmr.2000.15.12.2380
Caveolin-1 Reduces Osteosarcoma Metastases by Inhibiting c-Src Activity and Met Signaling, Cancer Research, vol.67, issue.16, pp.67-7675, 2007. ,
DOI : 10.1158/0008-5472.CAN-06-4697
Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis, Nature Medicine, vol.13, issue.1, pp.100-102, 2000. ,
DOI : 10.1038/sj.onc.1202235
The metastatic patterns of osteosarcoma, British Journal of Cancer, vol.32, issue.1, pp.87-107, 1975. ,
DOI : 10.1038/bjc.1975.136
Relationships between levels of CXCR4 and VEGF and blood-borne metastasis and survival in patients with osteosarcoma, Medical Oncology, vol.29, issue.2, pp.649-53, 2011. ,
DOI : 10.1007/s12032-010-9493-4
Messenger RNA Expression Levels of CXCR4 Correlate with Metastatic Behavior and Outcome in Patients with Osteosarcoma, Clinical Cancer Research, vol.11, issue.7, pp.2561-2568, 2005. ,
DOI : 10.1158/1078-0432.CCR-04-1089
Stromal cell-derived factor-1/CXCR4 enhanced motility of human osteosarcoma cells involves MEK1/2, ERK and NF-??B-dependent pathways, Journal of Cellular Physiology, vol.12, issue.1, pp.204-216, 2009. ,
DOI : 10.1002/jcp.21846
Chemokines and the Molecular Basis of Cancer Metastasis, New England Journal of Medicine, vol.345, issue.11, pp.345-833, 2001. ,
DOI : 10.1056/NEJM200109133451113
Involvement of chemokine receptors in breast cancer metastasis, Nature, issue.6824, pp.410-50, 2001. ,
Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells, Cancer Res, issue.24, pp.62-7328, 2002. ,
Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer, Cancer Res, issue.20, pp.62-5930, 2002. ,
Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs, International Journal of Cancer, vol.176, issue.11, pp.2586-94, 2009. ,
DOI : 10.1002/ijc.24665
Deletion of Yin Yang 1 Protein in Osteosarcoma Cells on Cell Invasion and CXCR4/Angiogenesis and Metastasis, Cancer Research, vol.68, issue.6, pp.68-1797, 2008. ,
DOI : 10.1158/0008-5472.CAN-07-5582
Expression of Functional Chemokine Receptors CXCR3 and CXCR4 on Human Melanoma Cells, Journal of Biological Chemistry, vol.276, issue.48, pp.276-45098, 2001. ,
DOI : 10.1074/jbc.M106912200
The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia, Blood, issue.2, pp.95-627, 2000. ,
The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines, Immunology Letters, vol.92, issue.1-2, pp.171-179, 2004. ,
DOI : 10.1016/j.imlet.2003.10.020
ERM proteins in cell adhesion and membrane dynamics, Trends in Cell Biology, vol.9, issue.5, pp.187-92, 1999. ,
DOI : 10.1016/S0962-8924(99)01544-5
Regulation mechanism of ERM (ezrin/radixin/moesin) protein/plasma membrane association: possible involvement of phosphatidylinositol turnover and Rho-dependent signaling pathway, The Journal of Cell Biology, vol.135, issue.1, pp.37-51, 1996. ,
DOI : 10.1083/jcb.135.1.37
Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway, Proceedings of the National Academy of Sciences, vol.96, issue.13, pp.96-7300, 1999. ,
DOI : 10.1073/pnas.96.13.7300
Ezrin, a key component in tumor metastasis, Trends in Molecular Medicine, vol.10, issue.5, pp.201-205, 2004. ,
DOI : 10.1016/j.molmed.2004.03.001
Ezrin in primary cutaneous melanoma, Modern Pathology, vol.258, issue.4, pp.503-513, 2005. ,
DOI : 10.1038/modpathol.3800300
Prognostic Impact of Immunohistochemical Expression of Ezrin in Highly Malignant Soft Tissue Sarcomas, Clinical Cancer Research, vol.11, issue.17, pp.6198-204, 2005. ,
DOI : 10.1158/1078-0432.CCR-05-0548
The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis, Nature Medicine, vol.10, issue.2, pp.182-188, 2004. ,
DOI : 10.1038/nm982
The actin-cytoskeleton linker protein ezrin is regulated during osteosarcoma metastasis by PKC, Oncogene, vol.58, issue.6, pp.792-802, 2009. ,
DOI : 10.1152/ajpcell.00111.2007
Metastasis-associated differences in gene expression in a murine model of osteosarcoma, Cancer Res, issue.9, pp.61-3750, 2001. ,
-1 Oncogenes in a Human Osteosarcoma, Japanese Journal of Cancer Research, vol.83, issue.1, pp.6-9, 1989. ,
DOI : 10.1111/j.1349-7006.1989.tb02236.x
URL : https://hal.archives-ouvertes.fr/hal-01208515
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis, Cancer Research, vol.64, issue.19, pp.64-7099, 2004. ,
DOI : 10.1158/0008-5472.CAN-04-1443
Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways, Molecular Cancer, vol.8, issue.1, p.118, 2009. ,
DOI : 10.1186/1476-4598-8-118
Insulin-like growth factor I correlations to changes of the hormonal status in puberty and age, Experimental and Clinical Endocrinology & Diabetes, vol.102, issue.04, pp.289-98, 1994. ,
DOI : 10.1055/s-0029-1211294
Serum Free Insulin-Like Growth Factor I (IGF-I), Total IGF-I, and IGF-Binding Protein-3 Concentrations in Normal Children and Children with Growth Hormone Deficiency, Journal of Clinical Endocrinology & Metabolism, vol.84, issue.1, pp.82-91, 1999. ,
DOI : 10.1210/jc.84.1.82
Insulin-like growth factor-I inhibits the progression of human U-2 OS osteosarcoma cells towards programmed cell death through interaction with the IGF-I receptor, Cell Mol Biol, vol.46, issue.1, pp.71-78, 2000. ,
Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth, Cancer Res, issue.10, pp.54-2803, 1994. ,
Inhibition of Metastatic Behavior of Murine Osteosarcoma by Hypophysectomy, JNCI Journal of the National Cancer Institute, vol.84, issue.12, pp.966-71, 1992. ,
DOI : 10.1093/jnci/84.12.966
Treatment of Metastatic Osteosarcoma With the Somatostatin Analog OncoLar: Significant Reduction of Insulin-Like Growth Factor-1 Serum Levels, Journal of Pediatric Hematology/Oncology, vol.24, issue.6, pp.24-440, 2002. ,
DOI : 10.1097/00043426-200208000-00007
A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy, Clin Cancer Res, vol.8, issue.7, pp.2406-2418, 2002. ,
Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits growth, reduces invasion, and enhances radiosensitivity in human osteosarcoma cells, Molecular and Cellular Biochemistry, vol.12, issue.1-2, pp.257-66, 2009. ,
DOI : 10.1007/s11010-009-0064-y
Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo, Molecular and Cellular Biochemistry, vol.82, issue.1-2, pp.225-258, 2010. ,
DOI : 10.1007/s11010-010-0453-2
Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF- 1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer, pp.50-1190, 2008. ,
R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr Blood Cancer, pp.67-75, 2010. ,
Increased expression of insulin-like growth factor-1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma, Journal of Surgical Oncology, vol.39, issue.3, 2011. ,
DOI : 10.1002/jso.22077
Dissecting the metastatic cascade, Nature Reviews Cancer, vol.19, issue.6, pp.448-56, 2004. ,
DOI : 10.1016/S0140-6736(98)10175-7
Models, mechanisms and clinical evidence for cancer dormancy, Nature Reviews Cancer, vol.20, issue.11, pp.834-880, 2007. ,
DOI : 10.1038/nrc2256
Ineffectiveness of Doxorubicin Treatment on Solitary Dormant Mammary Carcinoma Cells or Late-developing Metastases, Breast Cancer Research and Treatment, vol.2, issue.3, pp.199-206, 2003. ,
DOI : 10.1023/B:BREA.0000004377.12288.3c
Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression, Nature Medicine, vol.218, issue.2, pp.149-53, 1995. ,
DOI : 10.1016/0022-3468(93)90246-H
Cancer micrometastasis and tumour dormancy???, APMIS, vol.8, issue.6, pp.754-70, 2008. ,
DOI : 10.1111/j.1600-0463.2008.01033.x
A Model of Human Tumor Dormancy: An Angiogenic Switch From the Nonangiogenic Phenotype, JNCI Journal of the National Cancer Institute, vol.98, issue.5, pp.98-316, 2006. ,
DOI : 10.1093/jnci/djj068